BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES
Bio-Techne (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will be presenting at three major healthcare investor conferences in September 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will be presenting at three major healthcare investor conferences in September 2024. The presentations will take place at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4th at 4:05 PM EDT, the 2024 Wells Fargo Healthcare Conference on September 6th at 11:00 AM EDT, and the Baird 2024 Global Healthcare Conference on September 10th at 1:25 PM EDT.
Investors and interested parties can access live webcasts of these presentations through the IR Calendar page on Bio-Techne's Investor Relations website. This series of presentations offers an opportunity for the company to showcase its developments and strategies to a wide audience of healthcare investors and analysts.
Details
News Market Reaction – TECH
The recorded move for TECH in the trading session of this news was -1.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Morgan Stanley 22nd Annual Global Healthcare Conference
September 4, 2024
4:05 PM EDT
2024 Wells Fargo Healthcare Conference
September 6, 2024
11:00 AM EDT
Baird 2024 Global Healthcare Conference
September 10, 2024
1:25 PM EDT
A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Contact: | David Clair, Vice President, Investor Relations & Corporate Development |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-investor-healthcare-conferences-302228184.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.